These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
774 related articles for article (PubMed ID: 34412620)
1. Prevalence and associated characteristics of anti-SARS-CoV-2 antibodies in Mexico 5 months after pandemic arrival. Díaz-Salazar C; Sánchez-García A; Rodríguez-Gutiérrez R; Camacho-Ortiz A; Saldívar-Rodríguez D; González-González JG BMC Infect Dis; 2021 Aug; 21(1):835. PubMed ID: 34412620 [TBL] [Abstract][Full Text] [Related]
2. [Seroprevalence of anti-SARS-CoV-2 IgG/IgM antibodies in Borgosesia (Piedmont Region, Northern Italy) population: a surveillance strategy in post-lockdown period?]. Alessi D; Borré S; Barale A; Isabella A; Milano F; Rossi MA; Silano V; Piu N; Cena T; Faggiano F; Epidemiol Prev; 2020; 44(5-6 Suppl 2):200-206. PubMed ID: 33412811 [TBL] [Abstract][Full Text] [Related]
3. Seroprevalence of SARS-CoV-2 Infection in Portugal in May-July 2020: Results of the First National Serological Survey (ISNCOVID-19). Kislaya I; Gonçalves P; Barreto M; Sousa R; Garcia AC; Matos R; Guiomar R; Rodrigues AP; Acta Med Port; 2021 Feb; 34(2):87-94. PubMed ID: 33641702 [TBL] [Abstract][Full Text] [Related]
4. Detection of SARS-CoV-2-specific antibodies via rapid diagnostic immunoassays in COVID-19 patients. Chansaenroj J; Yorsaeng R; Posuwan N; Puenpa J; Sudhinaraset N; Chirathaworn C; Poovorawan Y Virol J; 2021 Mar; 18(1):52. PubMed ID: 33750394 [TBL] [Abstract][Full Text] [Related]
5. SARS-CoV-2 antibody seroprevalence in the general population and high-risk occupational groups across 18 cities in Iran: a population-based cross-sectional study. Poustchi H; Darvishian M; Mohammadi Z; Shayanrad A; Delavari A; Bahadorimonfared A; Eslami S; Javanmard SH; Shakiba E; Somi MH; Emami A; Saki N; Hormati A; Ansari-Moghaddam A; Saeedi M; Ghasemi-Kebria F; Mohebbi I; Mansour-Ghanaei F; Karami M; Sharifi H; Pourfarzi F; Veisi N; Ghadimi R; Eghtesad S; Niavarani A; Ali Asgari A; Sadeghi A; Sorouri M; Anushiravani A; Amani M; Kaveh S; Feizesani A; Tabarsi P; Keyvani H; Markarian M; Shafighian F; Sima A; Sadjadi A; Radmard AR; Mokdad AH; Sharafkhah M; Malekzadeh R Lancet Infect Dis; 2021 Apr; 21(4):473-481. PubMed ID: 33338441 [TBL] [Abstract][Full Text] [Related]
6. Highlighted Prospects of an IgM/IgG Antibodies Test in Identifying Individuals With Asymptomatic Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection. Li Y; He Q; Yu R; Jiang H; Wang W; Feng D; Hou G; Zhou H; Jiang Y; Xiang Z Arch Pathol Lab Med; 2021 Jan; 145(1):39-45. PubMed ID: 32966561 [TBL] [Abstract][Full Text] [Related]
7. SARS-CoV-2 seroprevalence trends in healthy blood donors during the COVID-19 outbreak in Milan. Valenti L; Bergna A; Pelusi S; Facciotti F; Lai A; Tarkowski M; Lombardi A; Berzuini A; Caprioli F; Santoro L; Baselli G; Ventura CD; Erba E; Bosari S; Galli M; Zehender G; Prati D; Blood Transfus; 2021 May; 19(3):181-189. PubMed ID: 33539289 [TBL] [Abstract][Full Text] [Related]
8. Serological investigation of asymptomatic cases of SARS-CoV-2 infection reveals weak and declining antibody responses. Yang Y; Wang X; Du RH; Zhang W; Si HR; Zhu Y; Shen XR; Li Q; Li B; Men D; Zhou YN; Wang H; Tong XL; Zhang XE; Shi ZL; Zhou P Emerg Microbes Infect; 2021 Dec; 10(1):905-912. PubMed ID: 33870851 [TBL] [Abstract][Full Text] [Related]
9. High SARS-CoV-2 IgG/IGM seroprevalence in asymptomatic Congolese in Brazzaville, the Republic of Congo. Batchi-Bouyou AL; Lobaloba Ingoba L; Ndounga M; Vouvoungui JC; Mfoutou Mapanguy CC; Boumpoutou KR; Ntoumi F Int J Infect Dis; 2021 May; 106():3-7. PubMed ID: 33370565 [TBL] [Abstract][Full Text] [Related]
10. Validation of a new automated chemiluminescent anti-SARS-CoV-2 IgM and IgG antibody assay system detecting both N and S proteins in Japan. Yokoyama R; Kurano M; Morita Y; Shimura T; Nakano Y; Qian C; Xia F; He F; Kishi Y; Okada J; Yoshikawa N; Nagura Y; Okazaki H; Moriya K; Seto Y; Kodama T; Yatomi Y PLoS One; 2021; 16(3):e0247711. PubMed ID: 33661990 [TBL] [Abstract][Full Text] [Related]
11. Epidemiology of SARS-CoV-2 antibodies among firefighters/paramedics of a US fire department: a cross-sectional study. Caban-Martinez AJ; Schaefer-Solle N; Santiago K; Louzado-Feliciano P; Brotons A; Gonzalez M; Issenberg SB; Kobetz E Occup Environ Med; 2020 Dec; 77(12):857-861. PubMed ID: 32764107 [TBL] [Abstract][Full Text] [Related]
12. Seroprevalence of Anti-SARS-CoV-2 Antibodies in Blood Donors from Nuevo Leon State, Mexico, during 2020: A Retrospective Cross-Sectional Evaluation. Martinez-Acuña N; Avalos-Nolazco DM; Rodriguez-Rodriguez DR; Martinez-Liu CG; Galan-Huerta KA; Padilla-Rivas GR; Ramos-Jimenez J; Ayala-de-la-Cruz S; Cienfuegos-Pecina E; Diaz-Chuc EA; Cazares-Tamez R; Flores-Arechiga A; Perez-Chavez F; Arellanos-Soto D; Lozano-Sepulveda SA; Garza-Gonzalez E; Treviño-Garza C; Montes-de-Oca-Luna R; Lee-Gonzalez AB; de-la-O-Cavazos ME; Rivas-Estilla AM Viruses; 2021 Jun; 13(7):. PubMed ID: 34202849 [TBL] [Abstract][Full Text] [Related]
13. Seroprevalence of anti-SARS-CoV-2 IgG antibodies in the staff of a public school system in the midwestern United States. Lopez L; Nguyen T; Weber G; Kleimola K; Bereda M; Liu Y; Accorsi EK; Skates SJ; Santa Maria JP; Smith KR; Kalinich M PLoS One; 2021; 16(6):e0243676. PubMed ID: 34111144 [TBL] [Abstract][Full Text] [Related]
14. Seroprevalence of Immunoglobulin M and G Antibodies against SARS-CoV-2 Virus: A Systematic Review and Meta-Analysis Study. Fathi M; Vakili K; Sayehmiri F; Mohamadkhani A; Ghanbari R; Hajiesmaeili M; Rezaei-Tavirani M Iran J Immunol; 2021 Mar; 18(1):34-46. PubMed ID: 33787512 [TBL] [Abstract][Full Text] [Related]
15. Seroprevalence of SARS-CoV-2-Specific IgG Antibodies Among Adults Living in Connecticut: Post-Infection Prevalence (PIP) Study. Mahajan S; Srinivasan R; Redlich CA; Huston SK; Anastasio KM; Cashman L; Massey DS; Dugan A; Witters D; Marlar J; Li SX; Lin Z; Hodge D; Chattopadhyay M; Adams MD; Lee C; Rao LV; Stewart C; Kuppusamy K; Ko AI; Krumholz HM Am J Med; 2021 Apr; 134(4):526-534.e11. PubMed ID: 33130124 [TBL] [Abstract][Full Text] [Related]
16. Seroprevalence of Unidentified SARS-CoV-2 Infection in Hong Kong During 3 Pandemic Waves. Boon SS; Wong MCS; Ng RWY; Leung DTM; Chen Z; Lai CKC; Ho WCS; Huang J; Wong BKC; Fung KSC; Chan PKS JAMA Netw Open; 2021 Nov; 4(11):e2132923. PubMed ID: 34779848 [TBL] [Abstract][Full Text] [Related]
17. Enhanced surveillance of COVID-19 in Scotland: population-based seroprevalence surveillance for SARS-CoV-2 during the first wave of the epidemic. Dickson E; Palmateer NE; Murray J; Robertson C; Waugh C; Wallace LA; Mathie L; Heatlie K; Mavin S; Gousias P; Von Wissman B; Goldberg DJ; McAuley A Public Health; 2021 Jan; 190():132-134. PubMed ID: 33453689 [TBL] [Abstract][Full Text] [Related]
18. Evaluation of serum IgM and IgG antibodies in COVID-19 patients by enzyme linked immunosorbent assay. Zhou C; Bu G; Sun Y; Ren C; Qu M; Gao Y; Zhu Y; Wang L; Sun L; Liu Y J Med Virol; 2021 May; 93(5):2857-2866. PubMed ID: 33331654 [TBL] [Abstract][Full Text] [Related]
19. Prevalence of SARS-CoV-2 antibodies among workers of the public higher education institutions of Porto, Portugal: a cross-sectional study. Meireles P; Amaro J; Pinto da Costa J; Lopes MM; Varandas T; Norton P; Guimarães JT; Severo M; Barros H Occup Environ Med; 2021 Sep; 78(9):648-653. PubMed ID: 34193594 [TBL] [Abstract][Full Text] [Related]
20. SARS-CoV-2 seroprevalence among blood donors after the first COVID-19 wave in Canada. Saeed S; Drews SJ; Pambrun C; Yi QL; Osmond L; O'Brien SF Transfusion; 2021 Mar; 61(3):862-872. PubMed ID: 33527398 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]